Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-25T06:53:15.368Z Has data issue: false hasContentIssue false

1794 – Augmentative Repetitive Transcranial Magnetic Stimulation (rtms) In The Acute Treatment Of Drug-resistant Depression

Published online by Cambridge University Press:  15 April 2020

G. Camuri
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy
B. Dell’Osso
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy
I. Guerrieri
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy
C. Arici
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy
L. Oldani
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy
A.C. Altamura
Affiliation:
Fondazione IRCCS Ca’ Granda, Department of Psychiatry, Milano, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

rTMS is a non invasive technique, used for the stimulation of the Dorsolateral Prefrontal Cortex (DLPFC) by means of coil-generated magnetic fields [1,2]. The present study was aimed to assess efficacy and tolerability of augmentative low and high frequency rTMS in TRD patients, with current moderate-severe major depressive episode.

Methods

24 patients with a diagnosis of drug-resistant Major Depressive Episode (Unipolar or Bipolar Depression) were treated with 4 weeks of rTMS. Subjects were randomly assigned to one of the following treatments: right DLPFC, 1 Hz, 110% of motor threshold (MT), 420 stimuli/day; right DLPFC, 1 Hz, 110% MT, 900 stimuli/day; left DLPFC, 10 Hz, 80% MT, 750 stimuli/day, according to safety guidelines [3]. Analyses were performed using t-test and ANOVA.

Results

3 subjects dropped out at the 1st or 2nd weeks of stimualtion. 21 patients completed the treatment, showing a statistically significant score reduction at HAM-D, MADRS, HAM-A e CGI-s (tr = 9.05, p < 0.005; tr = 7.93, p < 0.005; tr = 6.81, p < 0.005; tr = 4.37, p < 0.005). Response (reduction of HAM-D score of 50%) was achieved by 2 patients, one of whom considered remitter (HAM-D≤8). Partial response (reduction of HAM-D score between 25-50%) was obtained by 12 patients. No significant difference was observed in terms of efficacy between high vs low frequency. With respect to tolerability, only mild and transient side-effects were reported (discomfort, headache, insomnia). One patient withdrew because of hypomanic switch.

Conclusions

Both augmentative low and high-frequency rTMS appeared to be equally effective and well tolerated in the treatment of TRD.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.